Financial Comparison: Phibro Animal Health (NASDAQ:PAHC) & TriSalus Life Sciences (NASDAQ:TLSI)

TriSalus Life Sciences (NASDAQ:TLSI) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.

Volatility & Risk

TriSalus Life Sciences has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.

Profitability

This table compares TriSalus Life Sciences and Phibro Animal Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-98.45%	N/A	-111.88%
Phibro Animal Health	6.29%	38.28%	8.37%

Earnings & Valuation

This table compares TriSalus Life Sciences and Phibro Animal Health”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$29.43 million	8.06	-$30.05 million	($2.02)	-2.35
Phibro Animal Health	$1.30 billion	1.66	$48.26 million	$1.66	31.97

Phibro Animal Health has higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 27.5% of TriSalus Life Sciences shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for TriSalus Life Sciences and Phibro Animal Health, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1	1	2	0	2.25
Phibro Animal Health	2	2	2	1	2.29

TriSalus Life Sciences currently has a consensus price target of $11.00, suggesting a potential upside of 131.58%. Phibro Animal Health has a consensus price target of $34.40, suggesting a potential downside of 35.18%. Given TriSalus Life Sciences’ higher probable upside, equities research analysts clearly believe TriSalus Life Sciences is more favorable than Phibro Animal Health.

Summary

Phibro Animal Health beats TriSalus Life Sciences on 12 of the 14 factors compared between the two stocks.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal’s health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock’s diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.